Overview
GLP-1 receptor agonists have become one of the most active areas in metabolic research peptide literature. This brief overview summarizes published findings on Semaglutide, Tirzepatide, and the newer triple-agonist Retatrutide.
Receptor profiles
- Semaglutide — long-acting GLP-1 receptor agonist studied extensively in published clinical and preclinical literature.
- Tirzepatide — adds GIP receptor agonism to the GLP-1 backbone.
- Retatrutide — extends further to glucagon receptor agonism.
The three compounds differ in pharmacokinetics, receptor selectivity, and the magnitude of published metabolic effects.
Compliance
This article is informational only. All compounds in the XO Labs USA catalog are for research use only and not for human consumption. No medical, therapeutic, diagnostic, or treatment claims are made.
For research use only. Not for human consumption. No medical, therapeutic, diagnostic, or treatment claims are made for any item in the XO Labs USA catalog.